Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care
Authors' conclusion
Sex disparities in medication prescribing amongst T2DM patients were seen, including less starting with statins and potential undertreatment with RAAS-i in females. Such disparities may partly explain higher excess risks for cardiovascular and renal complications associated with diabetes observed in females.
Study context
- Population
- Primary care patients with T2D from the north of the Netherlands (GIANTT database), calendar year 201947% females
- Participants
- 10,456 patients
- Exposure
- Females vs males
- Outcome
- Prescribing quality indicators: prevalence, start, intensification and safety of glucose-, lipid-, blood pressure- and albuminuria-lowering medication
- Follow-up
- Calendar year 2019
Methodological detailsprimary care database (GIANTT), validated prescribing quality indicators, univariate logistic regression
- Primary care database (GIANTT)
- Validated prescribing quality indicators
- Univariate logistic regression
Main finding
As reported in the abstract
Prescribing quality indicators by sex
Females vs MalesOdds ratio (95% CI)
Metformin treatment: 81.7% vs. 86.5%
0.70(0.61–0.80)
RAAS-i when on multiple blood pressure-lowering medicines: 81.9% vs. 89.3%
0.55(0.46–0.64)
RAAS-i when having albuminuria: 74.7% vs. 82.1%
0.64(0.49–0.85)
Statin started: 19.7% vs. 24.7%
0.75(0.58–0.96)
Statin prescribed: 58.7% vs. 63.9%
0.80(0.73–0.89)
Observational data: associations, not effects.
Original publication
Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care. Diabet Med. Published 14 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →